Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert
Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview.
You may also be interested in...
Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.
Global Industry Welcomes World Health Organization’s Call For Widespread Oral Contraceptive Rx-To-OTC Switch
The Global Self-Care Industry Federation (previously the WSMI) welcomes a call from the World Health Organization to make oral contraceptive pills available OTC.
Teva and Polpharma's OTC operations in Poland are set to received a boost with the approval of two switches by national medicines regulator URPL. Polish consumers can now get OTC access to additional treatments for hay fever and cough.